ESMO Asia-Week 2021 - ESMO Asia Virtual Oncology Week 2021
Nov 17 - Nov 23, 2021 | SingaporeSingapore
LARVOL is not affiliated with ESMO Asia Virtual Oncology Week 2021 and all trademarks, logos, and brand names are property of their respective owners
Showing 4 abstracts linked to Trials
[VIRTUAL] ESMO Virtual Plenary - Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial
[VIRTUAL] ESMO Virtual Plenary - ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy
[VIRTUAL] ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy
[VIRTUAL] Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial